- SEK12.88bn
- SEK12.36bn
- SEK1.54bn
Brief: Biogaia Becomes 100 Percent Shareholder Of Metabogen
Brief: Biogaia Opens Up New Subsidiary In Finland
Brief: Biogaia Q1 Operating Profit Up At SEK 64.2 Million
Brief: Biogaia: Combination Of L. Reuteri Strains Reduces Symptoms In Children With Sore Throat
Brief: Biogaia Signs Exclusive Agreement In Egypt
Brief: Biogaia Invest Says New Subsidiary Focusing On Investments To Support Growth Of Biogaia
Brief: Biogaia: MetaboGen Reached New Crucial Milestone In Its Development Of Novel Probiotic Products
Brief: Biogaia Q4 Operating Profit Falls To SEK 45.3 Million
Brief: BioGaia revises dividend policy
Brief: Biogaia Invests In Sweden, Launches Its Entire Adult Health Portfolio
Brief: Biogaia Has Carried Out A Directed Issue Of 2.86 Million Class B Shares, Raising Proceeds Of Sek 1.1 Billion
Brief: Biogaia Intends To Carry Out Directed Share Issue Of Up To SEK 1.1 Billion
Brief: Biogaia Q3 Operating Profit Down At SEK 27.0 Million
Brief: Biogaia Says Estimates That Sales And Earnings Will Be Negatively Affected Both In Q3 And Q4 2020
Brief: Biogaia's Board Believes That It Is Justified To Withdraw Proposal For An Extra Dividend
Brief: Biogaia Q2 Net Sales Up At SEK 244.7 Mln
Brief: BioGaia Q1 Operating Profit Rises To SEK 55.6 Million
Brief: Biogaia's Says Previously Proposed Extra Dividend Of Sek 4.25 Per Share Is Cancelled
Brief: Biogaia AB Says At Biogaia Production, Manufacturing Is Running Without Disruptions